Bath & Body Works, Inc. (BBWI) Cash Flow Statement

Bath & Body Works, Inc. (BBWI) generated $1.3B of operating cash flow over the twelve months to 2026-08-01, spent $242.0M on capital expenditure and had free cash flow of $1.0B, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-08-01 · read by EquiReason

BBWIBath & Body Works, Inc.Follow BBWI — free

Specialty Retail · Consumer Cyclical

—

Price chart with a free account

Market cap: 4.2B
P/E TTM: 5.5
Dividend yield: 3.8%
52-week: —
Next earnings: 18 Nov, in 25 days

Line	FY2010 Jan 10	FY2011 Jan 11	FY2012 Jan 12	FY2013 Feb 13	FY2014 Feb 14	FY2015 Jan 15	FY2016 Jan 16	FY2017 Jan 17	FY2018 Feb 18	FY2019 Feb 19	FY2021 Jan 21	FY2022 Jan 22	FY2023 Jan 23	FY2024 Feb 24	FY2025 Feb 25	FY2026 Jan 26	TTM Aug 26
Operating cash flow	1.17	1.28	1.27	1.35	1.25	1.79	2.03	1.99	1.41	1.38	2.04	1.49	1.14	0.95	0.89	1.10	1.27
Capital expenditure	0.20	0.27	0.43	0.59	0.69	0.72	0.73	0.99	0.71	0.63	0.23	0.27	0.33	0.30	0.23	0.24	-0.24
Free cash flow	0.97	1.01	0.84	0.76	0.56	1.07	1.30	1.00	0.70	0.75	1.81	1.22	0.82	0.66	0.66	0.87	1.03
Dividends paid	0.19	1.49	1.14	1.45	0.35	0.69	1.17	1.27	0.69	0.67	0.08	0.12	0.19	0.18	0.18	0.17	—
Share repurchases	0.00	0.21	1.19	0.63	0.06	0.09	0.48	0.44	0.45	0.20	0.00	1.96	1.31	0.15	0.40	0.40	—
Stock-based compensation	0.04	0.06	0.05	0.07	0.09	0.09	0.10	0.10	0.10	0.10	0.05	0.05	0.04	0.04	0.04	0.03	—

USD billions · SEC XBRL

Bath & Body Works, Inc. — questions

What is Bath & Body Works, Inc.'s operating cash flow?: $1.3B over the twelve months to 2026-08-01.
How much does Bath & Body Works, Inc. spend on capital expenditure?: $242.0M over the twelve months to 2026-08-01.
What is Bath & Body Works, Inc.'s free cash flow?: $1.0B over the twelve months to 2026-08-01: operating cash flow minus capital expenditure.

Every figure on this page comes from Bath & Body Works, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.